


Substitute for form 1449/PTO				<i>Complete if Known</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/584,837
Sheet 1 of 1				§ 371 Date	February 13, 2007
				First Named Inventor	Chikao MORIMOTO
				Art Unit	1635
				Examiner Name	Chong, Kimberly
				Attorney Docket Number	2144.0150002/RWE



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if Known)	MM-DD-YYYY		
US1		6,017,729	01-25-2000	Anderson <i>et al.</i>	
US2					
US3					
US4					
US5					
US6					
US7					
US8					
US9					
US10					
US11					
US12					
US13					
US14					
US15					
US16					
US17					
US18					
US19					
US20					

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		
	FP1				
	FP2				
	FP3				
	FP4				
	FP5				
	FP6				
	FP7				
	FP8				
	FP9				

799486_1.DOC

Examiner Signature	Date Considered
--------------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/584,837
				§ 371 Date	February 13, 2007
				First Named Inventor	Chikao MORIMOTO
				Art Unit	1635
				Examiner Name	Chong, Kimberly
Sheet	1	of	1	Attorney Docket Number	2144.0150002/RWE



NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	NPL26	BIOSIS, Accession No. PREV199192004874, Bosis abstract for Valle, A. <i>et al.</i> , <i>Int. Immunol.</i> 3:229-236, Oxford University Press (1991)			
	NPL27	BIOSIS, Accession No. PREV199799590112, Bosis abstract for Blazquez, M.V. <i>et al.</i> , <i>Protoplasma</i> 197:26-33, Springer-Verlag Wien (1997)			
	NPL28	BIOSIS, Accession No. PREV200300053191, Bosis abstract for Bozinovski, S. <i>et al.</i> , <i>J. Biol. Chem.</i> 277:42808-42814, The American Society for Biochemistry and Molecular Biology, Inc. (November 2002)			
	NPL29	Bosisio, D. <i>et al.</i> , "Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon- γ : a molecular basis for priming and synergism with bacterial lipopolysaccharide," <i>Blood</i> 99:3427-3431, The American Society of Hematology (May 2002)			
	NPL30	Burns, K. <i>et al.</i> , "Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4," <i>J. Exp. Med.</i> 197:263-268, The Rockefeller University Press (2003)			
	NPL31	Cao, Z. <i>et al.</i> , "IRAK: A Kinase Associated with the Interleukin-1 Receptor," <i>Sci.</i> 271:1128-1131, American Association for the Advancement of Science (1996)			
	NPL32	Cooke, E.-L. <i>et al.</i> , "Functional analysis of the interleukin-1-receptor-associated kinase (IRAK-1) in interleukin-1 β -stimulated nuclear factor κ B (NF- κ B) pathway activation: IRAK-1 associates with the NF- κ B essential modulator (NEMO) upon receptor stimulation," <i>Biochem. J.</i> 359:403-410, Portland Press on behalf of the Biochemical Society (2001)			
	NPL33	Hegen, M. <i>et al.</i> , "Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase," <i>Immunol.</i> 90:257-264, Blackwell Scientific Publications, Inc. (1997)			
	NPL34	MEDLINE Accession No. NLM11960013, Medline abstract for Li, S. <i>et al.</i> , <i>Proc. Nat'l Acad. Sci. USA</i> 99:5567-5572, National Academy of Sciences (April 2002)			

799498_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.